Recent Finacing
Recent Raise
Amal Therapeutics is a Geneva-based biotech developing peptide- and protein-based therapeutic cancer vaccines using its KISIMA cell-penetrating, multi‑antigenic, TLR‑agonist platform; lead candidate ATP128 targets metastatic colorectal cancer in preclinical development.
